Medicine and Dentistry
Glioblastoma
100%
Chordoma
80%
Therapeutic Procedure
75%
Surgery
58%
Diagnosis
45%
Epidermal Growth Factor Receptor
40%
Neuro-Oncology
40%
Facet Joint
40%
Regorafenib
40%
Targeted Therapy
40%
Progression Free Survival
40%
Neoplasm
40%
Cervical Spine
40%
Personalized Medicine
40%
Injury
40%
Aminolevulinic Acid
40%
Intracranial Tumor
40%
Systematic Review
40%
Analysis
36%
Methylation
31%
Ganglioglioma
30%
Overall Survival
30%
Telomerase
30%
Patient
28%
Promoter Region
26%
Mitogen-Activated Protein Kinase
25%
Age
23%
Surgical Approach
20%
Nerve Root
20%
Operating Room
20%
Meta-Analysis
20%
Epidermal Growth Factor Receptor
20%
Polytrauma
20%
Combination Therapy
20%
Delayed Diagnosis
20%
Discectomy
20%
Tumor Cell
20%
Corpectomy
20%
Absence
20%
Symptom
20%
Complication
20%
Blood Brain Barrier
15%
Semaphorin
15%
Protein
15%
Female
13%
Vasculotropin
13%
Receptor
13%
Antibody
10%
Adjuvant Radiotherapy
10%
Clinical Study
10%
Neuroscience
Glioma
50%
Aminolevulinic Acid
40%
Chordoma
40%
Regorafenib
40%
Methylation
31%
Telomerase
30%
Fluorescence
30%
Promoter Region
26%
Mitogen-Activated Protein Kinase
25%
Meta-Analysis
20%
Blood Brain Barrier
15%
Protein
15%
Semaphorin
15%
Eicosanoid Receptor
13%
Predictor
10%
Tumor of Central Nervous System
10%
Antibodies
10%
Epigenetics
5%
Gene
5%
Brain Tumor
5%
Gene Expression
5%
Tumor Marker
5%
Protoporphyrin
5%
In Vitro
5%
In Vivo
5%
DNA
5%
Mental Retardation Malformation Syndrome
5%
Immunofluorescence
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chordoma
40%
Regorafenib
40%
Progression Free Survival
40%
Aminolevulinic Acid
40%
Neoplasm
35%
Glioma
30%
Mitogen Activated Protein Kinase
25%
Overall Survival
25%
Complication
20%
Glioblastoma
20%
Protein
15%
Semaphorin
15%
Survival Rate
10%
Antibody
10%
Prognosis
10%
Protoporphyrin IX
5%
Paraffin
5%
Isocitrate Dehydrogenase 1
5%
Tumor Marker
5%
Syndrome X
5%
DNA
5%
